Detalhe da pesquisa
1.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med
; 376(11): 1015-1026, 2017 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28212060
2.
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.
Cancer Immunol Immunother
; 62(1): 137-47, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22865266
3.
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Eur Urol
; 83(1): 15-26, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36055895
4.
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
Eur Urol Oncol
; 2023 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37940446
5.
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
J Clin Oncol
; 41(22): 3839-3850, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290035
6.
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Eur Urol
; 82(1): 22-30, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35397952
7.
Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity.
J Immunol
; 183(6): 3682-9, 2009 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19692636
8.
Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts.
Eur J Immunol
; 39(11): 3121-33, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19839008
9.
Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays.
Sci Rep
; 9(1): 114, 2019 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30643180
10.
Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26].
Eur Urol
; 83(3): e87, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528479
11.
Tumor-specific T cells signal tumor destruction via the lymphotoxin beta receptor.
J Transl Med
; 5: 14, 2007 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-17355640
12.
Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines.
J Transl Med
; 5: 56, 2007 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-18001476
13.
Development of antitumor immune responses in reconstituted lymphopenic hosts.
Cancer Res
; 62(14): 3914-9, 2002 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12124318
14.
Active-specific immunotherapy for non-small cell lung cancer.
J Thorac Dis
; 3(2): 105-14, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22263073
15.
Signaling through OX40 enhances antitumor immunity.
Semin Oncol
; 37(5): 524-32, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21074068
16.
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.
Curr Mol Med
; 9(6): 673-82, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19689294
17.
Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein.
J Immunother
; 31(1): 43-51, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18157011
18.
Immunotherapy for melanoma: the good, the bad, and the future.
Curr Oncol Rep
; 7(5): 383-92, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16091201
19.
TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.
J Immunol
; 170(4): 2004-13, 2003 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12574370
20.
Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.
Immunology
; 108(3): 409-19, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12603608